ROYCHOUDHURY S , DAS A , SENGUPTA P , et al . Viral pandemics of the last four decades: pathophysiology, health impacts and perspectives [J ] . International Journal of Environmental Research and Public Health , 2020 , 17 ( 24 ): 9411 .

AKIN L , GÖZEL M G . Understanding dynamics of pandemics [J ] . Turkish Journal of Medical Sciences , 2020 , 50(SI-1): 515- 519 .

MEYER H , EHMANN R , SMITH G L . Smallpox in the post-eradication era [J ] . Viruses , 2020 , 12 ( 2 ): 138 .

AHMED R , BURTON D R . Viral vaccines: past successes and future challenges [J ] . Current Opinion in Virology , 2013 , 3 ( 3 ): 307 - 308 .

BRISSE M , VRBA S M , KIRK N , et al . Emerging concepts and technologies in vaccine development [J ] . Frontiers in Immunology , 2020 , 11 : 583077 .

MENG F K , ELLIS T . The second decade of synthetic biology: 2010—2020 [J ] . Nature Communications , 2020 , 11 : 5174 .

HO C , MORSUT L . Novel synthetic biology approaches for developmental systems [J ] . Stem Cell Reports , 2021 , 16 ( 5 ): 1051 - 1064 .

TAN X , LETENDRE J H , COLLINS J J , et al . Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics [J ] . Cell , 2021 , 184 ( 4 ): 881 - 898 .

WANG N X , YUAN Z , NIU W , et al . Synthetic biology approach for the development of conditionally replicating HIV-1 vaccine [J ] . Journal of Chemical Technology and Biotechnology , 2017 , 92 ( 3 ): 455 - 462 .

GHATTAS M , DWIVEDI G , LAVERTU M , et al . Vaccine technologies and platforms for infectious diseases: current progress, challenges, and opportunities [J ] . Vaccines , 2021 , 9 ( 12 ): 1490 .

AWADASSEID A , WU Y L , TANAKA Y , et al . Current advances in the development of SARS-CoV-2 vaccines [J ] . International Journal of Biological Sciences , 2021 , 17 ( 1 ): 8 - 19 .

ARORA M , LAKSHMI R . Vaccines-safety in pregnancy [J ] . Best Practice & Research Clinical Obstetrics & Gynaecology , 2021 , 76 : 23 - 40 .

CURRAN M P , LEROUX-ROELS I . Inactivated split-virion seasonal influenza vaccine (Fluarix): a review of its use in the prevention of seasonal influenza in adults and the elderly [J ] . Drugs , 2010 , 70 ( 12 ): 1519 - 1543 .

CHEN H P , HUANG Z Y , CHANG S Y , et al . Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: a multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial [J ] . Vaccine , 2022 , 40 ( 36 ): 5322 - 5332 .

STANFIELD B A , KOUSOULAS K G , FERNANDEZ A , et al . Rational design of live-attenuated vaccines against herpes simplex viruses [J ] . Viruses , 2021 , 13 ( 8 ): 1637 .

MOK D Z L , CHAN K R . The effects of pre-existing antibodies on live-attenuated viral vaccines [J ] . Viruses , 2020 , 12 ( 5 ): 520 .

VETTER V , DENIZER G , FRIEDLAND L R , et al . Understanding modern-day vaccines: what you need to know [J ] . Annals of Medicine , 2018 , 50 ( 2 ): 110 - 120 .

MOYLE P M , TOTH I . Modern subunit vaccines: development, components, and research opportunities [J ] . ChemMedChem , 2013 , 8 ( 3 ): 360 - 376 .

HANSSON M , NYGREN P A , STÅHL S . Design and production of recombinant subunit vaccines [J ] . Biotechnology and Applied Biochemistry , 2000 , 32 ( 2 ): 95 - 107 .

ZHANG N R , ZHENG B J , LU L , et al . Advancements in the development of subunit influenza vaccines [J ] . Microbes and Infection , 2015 , 17 ( 2 ): 123 - 134 .

AZMI F , AL HADI AHMAD FUAAD A , SKWARCZYNSKI M , et al . Recent progress in adjuvant discovery for peptide-based subunit vaccines [J ] . Human Vaccines & Immunotherapeutics , 2014 , 10 ( 3 ): 778 - 796 .

MCVOY M A . Cytomegalovirus vaccines [J ] . Clinical Infectious Diseases , 2013 , 57 ( suppl_4 ): S196 - S199 .

PASS R F , ZHANG C P , EVANS A , et al . Vaccine prevention of maternal cytomegalovirus infection [J ] . The New England Journal of Medicine , 2009 , 360 ( 12 ): 1191 - 1199 .

TOMBÁCZ I , WEISSMAN D , PARDI N . Vaccination with messenger RNA: a promising alternative to DNA vaccination [J ] . Methods in Molecular Biology , 2021 , 2197 : 13 - 31 .

GRANT-KLEIN R J , ALTAMURA L A , BADGER C V , et al . Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges [J ] . Human Vaccines & Immunotherapeutics , 2015 , 11 ( 8 ): 1991 - 2004 .

LEDWITH B J , MANAM S , TROILO P J , et al . Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice [J ] . Intervirology , 2000 , 43 ( 4/5/6 ): 258 - 272 .

WANG Z , TROILO P J , WANG X , et al . Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation [J ] . Gene Therapy , 2004 , 11 ( 8 ): 711 - 721 .

SZABÓ G T , MAHINY A J , VLATKOVIC I . COVID-19 mRNA vaccines: platforms and current developments [J ] . Molecular Therapy , 2022 , 30 ( 5 ): 1850 - 1868 .

KARIKÓ K . Developing mRNA for therapy [J ] . The Keio Journal of Medicine , 2022 , 71 ( 1 ): 31 .

LI M Y , WANG Z N , XIE C Y , et al . Advances in mRNA vaccines [J ] . International Review of Cell and Molecular Biology , 2022 , 372 : 295 - 316 .

WANG Y , ZHANG Z Q , LUO J W , et al . mRNA vaccine: a potential therapeutic strategy [J ] . Molecular Cancer , 2021 , 20 ( 1 ): 33 .

FANG E Y , LIU X H , LI M , et al . Advances in COVID-19 mRNA vaccine development [J ] . Signal Transduction and Targeted Therapy , 2022 , 7 : 94 .

MCCANN N , O'CONNOR D , LAMBE T , et al . Viral vector vaccines [J ] . Current Opinion in Immunology , 2022 , 77 : 102210 .

EWER K J , LAMBE T , ROLLIER C S , et al . Viral vectors as vaccine platforms: from immunogenicity to impact [J ] . Current Opinion in Immunology , 2016 , 41 : 47 - 54 .

CHEN J D , WANG J H , ZHANG J P , et al . Advances in development and application of influenza vaccines [J ] . Frontiers in Immunology , 2021 , 12 : 711997 .

DE VRIES R D , RIMMELZWAAN G F . Viral vector-based influenza vaccines [J ] . Human Vaccines & Immunotherapeutics , 2016 , 12 ( 11 ): 2881 - 2901 .

KHAN M S , KIM E , MCPHERSON A , et al . Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein [J ] . Antibody Therapeutics , 2022 , 5 ( 3 ): 177 - 191 .

TOURNIER J N , KONONCHIK J . Virus eradication and synthetic biology: changes with SARS-CoV-2? [J ] . Viruses , 2021 , 13 ( 4 ): 569 .

PARVATHY S T , UDAYASURIYAN V , BHADANA V . Codon usage bias [J ] . Molecular Biology Reports , 2022 , 49 ( 1 ): 539 - 565 .

XU Y C , LIU K S , HAN Y , et al . Codon usage bias regulates gene expression and protein conformation in yeast expression system P. pastoris [J ] . Microbial Cell Factories , 2021 , 20 ( 1 ): 91 .

NOVOA E M , PAVON-ETERNOD M , PAN T , et al . A role for tRNA modifications in genome structure and codon usage [J ] . Cell , 2012 , 149 ( 1 ): 202 - 213 .

NOVOA E M , RIBAS DE POUPLANA L . Speeding with control: codon usage, tRNAs, and ribosomes [J ] . Trends in Genetics , 2012 , 28 ( 11 ): 574 - 581 .

GUIMARAES J C , MITTAL N , GNANN A , et al . A rare codon-based translational program of cell proliferation [J ] . Genome Biology , 2020 , 21 ( 1 ): 44 .

FU H G , LIANG Y B , ZHONG X Q , et al . Codon optimization with deep learning to enhance protein expression [J ] . Scientific Reports , 2020 , 10 ( 1 ): 17617 .

FENG L Q , WANG Q , SHAN C , et al . An adenovirus-vectored COVID-19 vaccine confers protection from SARS-CoV-2 challenge in rhesus macaques [J ] . Nature Communications , 2020 , 11 : 4207 .

XU S Q , YANG K P , LI R , et al . mRNA vaccine era-mechanisms, drug platform and clinical prospection [J ] . International Journal of Molecular Sciences , 2020 , 21 ( 18 ): 6582 .

COLEMAN J R , PAPAMICHAIL D , SKIENA S , et al . Virus attenuation by genome-scale changes in codon pair bias [J ] . Science , 2008 , 320 ( 5884 ): 1784 - 1787 .

BROADBENT A J , SANTOS C P , ANAFU A , et al . Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets [J ] . Vaccine , 2016 , 34 ( 4 ): 563 - 570 .

KAPLAN B S , SOUZA C K , GAUGER P C , et al . Vaccination of pigs with a codon-pair bias de-optimized live attenuated influenza vaccine protects from homologous challenge [J ] . Vaccine , 2018 , 36 ( 8 ): 1101 - 1107 .

MARUGGI G , ZHANG C L , LI J W , et al . mRNA as a transformative technology for vaccine development to control infectious diseases [J ] . Molecular Therapy , 2019 , 27 ( 4 ): 757 - 772 .

BURNS C C , SHAW J , CAMPAGNOLI R , et al . Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region [J ] . Journal of Virology , 2006 , 80 ( 7 ): 3259 - 3272 .

SI L L , XU H , ZHOU X Y , et al . Generation of influenza A viruses as live but replication-incompetent virus vaccines [J ] . Science , 2016 , 354 ( 6316 ): 1170 - 1173 .

JOHNSON B A , XIE X P , BAILEY A L , et al . Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis [J ] . Nature , 2021 , 591 ( 7849 ): 293 - 299 .

GOŁAWSKI M , LEWANDOWSKI P , JABŁOŃSKA I , et al . The reassessed potential of SARS-CoV-2 attenuation for COVID-19 vaccine development - a systematic review [J ] . Viruses , 2022 , 14 ( 5 ): 991 .

WANG Y , YANG C , SONG Y T , et al . Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy [J ] . Proceedings of the National Academy of Sciences of the United States of America , 2021 , 118 ( 29 ): e2102775118 .

FAN R L Y , VALKENBURG S A , WONG C K S , et al . Generation of live attenuated influenza virus by using codon usage bias [J ] . Journal of Virology , 2015 , 89 ( 21 ): 10762 - 10773 .

ASRANI K H , FARELLI J D , STAHLEY M R , et al . Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA [J ] . RNA Biology , 2018 , 15 ( 6 ): 756 - 762 .

TREPOTEC Z , ANEJA M K , GEIGER J , et al . Maximizing the translational yield of mRNA therapeutics by minimizing 5′-UTRs [J ] . Tissue Engineering Part A , 2019 , 25 ( 1/2 ): 69 - 79 .

VON NIESSEN A G O , POLEGANOV M A , RECHNER C , et al . Improving mRNA-based therapeutic gene delivery by expression-augmenting 3′ UTRs identified by cellular library screening [J ] . Molecular Therapy , 2019 , 27 ( 4 ): 824 - 836 .

PARDI N , HOGAN M J , WEISSMAN D . Recent advances in mRNA vaccine technology [J ] . Current Opinion in Immunology , 2020 , 65 : 14 - 20 .

LEE S , RYU J H . Influenza viruses: innate immunity and mRNA vaccines [J ] . Frontiers in Immunology , 2021 , 12 : 710647 .

NOORI M , NEJADGHADERI S A , ARSHI S , et al . Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: a systematic review of in vitro studies [J ] . Reviews in Medical Virology , 2022 , 32 ( 2 ): e2277 .

FEIKIN D R , HIGDON M M , ABU-RADDAD L J , et al . Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression [J ] . The Lancet , 2022 , 399 ( 10328 ): 924 - 944 .

XI J X , LEI L R , ZOUZAS W , et al . Nasally inhaled therapeutics and vaccination for COVID-19: developments and challenges [J ] . MedComm , 2021 , 2 ( 4 ): 569 - 586 .

ANDRADE V M , CHRISTENSEN-QUICK A , AGNES J , et al . INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants [J ] . Npj Vaccines , 2021 , 6 : 121 .

SMITH T R F , PATEL A , RAMOS S , et al . Immunogenicity of a DNA vaccine candidate for COVID-19 [J ] . Nature Communications , 2020 , 11 : 2601 .

WALTERS J N , SCHOUEST B , PATEL A , et al . Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates [J ] . Vaccine , 2022 , 40 ( 21 ): 2960 - 2969 .

DEY A , CHOZHAVEL RAJANATHAN T M , CHANDRA H , et al . Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models [J ] . Vaccine , 2021 , 39 ( 30 ): 4108 - 4116 .

KHOBRAGADE A , BHATE S , RAMAIAH V , et al . Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India [J ] . The Lancet , 2022 , 399 ( 10332 ): 1313 - 1321 .

ALMEIDA A M , EUSÉBIO D , QUEIROZ J A , et al . Minicircle DNA vaccine purification and E7 antigen expression assessment [J ] . Methods in Molecular Biology , 2021 , 2197 : 207 - 222 .

JIANG Y L , GAO X , XU K , et al . A novel cre recombinase-mediated in vivo minicircle DNA (CRIM) vaccine provides partial protection against Newcastle disease virus [J ] . Applied and Environmental Microbiology , 2019 , 85 ( 14 ): e00407 - e00419 .

ZHOU X W , JIANG X , QU M Y , et al . Engineering antiviral vaccines [J ] . ACS Nano , 2020 , 14 ( 10 ): 12370 - 12389 .

TATSIS N , ERTL H C J . Adenoviruses as vaccine vectors [J ] . Molecular Therapy , 2004 , 10 ( 4 ): 616 - 629 .

SAKURAI F , TACHIBANA M , MIZUGUCHI H . Adenovirus vector-based vaccine for infectious diseases [J ] . Drug Metabolism and Pharmacokinetics , 2022 , 42 : 100432 .

SHIRLEY J L , DE JONG Y P , TERHORST C , et al . Immune responses to viral gene therapy vectors [J ] . Molecular Therapy , 2020 , 28 ( 3 ): 709 - 722 .

TOMORI O , KOLAWOLE M O . Ebola virus disease: current vaccine solutions [J ] . Current Opinion in Immunology , 2021 , 71 : 27 - 33 .

YAMAZAKI K I , DE MORA K , SAITOH K . BioBrick-based 'quick gene assembly' in vitro [J ] . Synthetic Biology , 2017 , 2 ( 1 ): ysx003 .

SHETTY R P , ENDY D , KNIGHT T F . Engineering BioBrick vectors from BioBrick parts [J ] . Journal of Biological Engineering , 2008 , 2 : 5 .

NOORAEI S , BAHRULOLUM H , HOSEINI Z S , et al . Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers [J ] . Journal of Nanobiotechnology , 2021 , 19 ( 1 ): 59 .

PATEL J M , KIM M C , VARTABEDIAN V F , et al . Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses [J ] . Nanomedicine: Nanotechnology, Biology, and Medicine , 2015 , 11 ( 5 ): 1097 - 1107 .

MOHSEN M O , ZHA L S , CABRAL-MIRANDA G , et al . Major findings and recent advances in virus-like particle (VLP)-based vaccines [J ] . Seminars in Immunology , 2017 , 34 : 123 - 132 .

LAMPINEN V , HEINIMÄKI S , LAITINEN O H , et al . Modular vaccine platform based on the norovirus-like particle [J ] . Journal of Nanobiotechnology , 2021 , 19 ( 1 ): 25 .

COHEN A A , GNANAPRAGASAM P N P , LEE Y E , et al . Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice [J ] . Science , 2021 , 371 ( 6530 ): 735 - 741 .

CHARLTON HUME H K , VIDIGAL J , CARRONDO M J T , et al . Synthetic biology for bioengineering virus-like particle vaccines [J ] . Biotechnology and Bioengineering , 2019 , 116 ( 4 ): 919 - 935 .

TEYMENNET-RAMÍREZ K V , MARTÍNEZ-MORALES F , TREJO-HERNÁNDEZ M R . Yeast surface display system: strategies for improvement and biotechnological applications [J ] . Frontiers in Bioengineering and Biotechnology , 2021 , 9 : 794742 .

KUMAR R , KUMAR P . Yeast-based vaccines: new perspective in vaccine development and application [J ] . FEMS Yeast Research , 2019 , 19 ( 2 ): foz007 .

POLLET J , CHEN W H , VERSTEEG L , et al . SARS‑CoV-2 RBD219-N1C1: a yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice [J ] . Human Vaccines & Immunotherapeutics , 2021 , 17 ( 8 ): 2356 - 2366 .

LEE J , LIU Z Y , CHEN W H , et al . Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1 [J ] . Applied Microbiology and Biotechnology , 2021 , 105 ( 10 ): 4153 - 4165 .

ZHAO Q J , TOWNE V , BROWN M , et al . In-depth process understanding of RECOMBIVAX HB ® maturation and potential epitope improvements with redox treatment: multifaceted biochemical and immunochemical characterization [J ] . Vaccine , 2011 , 29 ( 45 ): 7936 - 7941 .

WANG J W , RODEN R B . Virus-like particles for the prevention of human papillomavirus-associated malignancies [J ] . Expert Review of Vaccines , 2013 , 12 ( 2 ): 129 - 141 .

VENTER J C , GLASS J I , HUTCHISON C A Ⅲ , et al . Synthetic chromosomes, genomes, viruses, and cells [J ] . Cell , 2022 , 185 ( 15 ): 2708 - 2724 .

WANG W H , ERAZO E M , ISHCOL M R C , et al . Virus-induced pathogenesis, vaccine development, and diagnosis of novel H7N9 avian influenza A virus in humans: a systemic literature review [J ] . The Journal of International Medical Research , 2020 , 48 ( 1 ): 300060519845488 .

TRIPATHI N K , SHRIVASTAVA A . Recent developments in recombinant protein-based dengue vaccines [J ] . Frontiers in Immunology , 2018 , 9 : 1919 .

PENG X L , CHENG J S Y , GONG H L , et al . Advances in the design and development of SARS-CoV-2 vaccines [J ] . Military Medical Research , 2021 , 8 ( 1 ): 67 .

CALZAS C , CHEVALIER C . Innovative mucosal vaccine formulations against influenza A virus infections [J ] . Frontiers in Immunology , 2019 , 10 : 1605 .

NAGY G , EMODY L , PÁL T . Strategies for the development of vaccines conferring broad-spectrum protection [J ] . International Journal of Medical Microbiology: IJMM , 2008 , 298 ( 5/6 ): 379 - 395 .

SÁNCHEZ-SAMPEDRO L , PERDIGUERO B , MEJÍAS-PÉREZ E , et al . The evolution of poxvirus vaccines [J ] . Viruses , 2015 , 7 ( 4 ): 1726 - 1803 .

CUNNINGHAM A L , GARÇON N , LEO O , et al . Vaccine development: from concept to early clinical testing [J ] . Vaccine , 2016 , 34 ( 52 ): 6655 - 6664 .

LI Z H , SONG S , HE M Z , et al . Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity [J ] . Nature Communications , 2018 , 9 : 5360 .

DE GROOT A S , MOISE L , TERRY F , et al . Better epitope discovery, precision immune engineering, and accelerated vaccine design using immunoinformatics tools [J ] . Frontiers in Immunology , 2020 , 11 : 442 .

ANTIA R , AHMED H , BULL J J . Directed attenuation to enhance vaccine immunity [J ] . PLoS Computational Biology , 2021 , 17 ( 2 ): e1008602 .

HAMMARLUND E , LEWIS M W , HANSEN S G , et al . Duration of antiviral immunity after smallpox vaccination [J ] . Nature Medicine , 2003 , 9 ( 9 ): 1131 - 1137 .